Business
Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+ NOT FOR RELEASE OR DISTRIBUTION IN THE UNIT...
About this update from Conavi Medical Corp.
[{"type":"text","content":"Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants\n\n\n\n\n PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+\n \n\n\n\n\n NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES\n \n\n\n TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (\n \n TSXV: CNVI\n \n ) (“\n \n Conavi\n \n\n Medical\n \n ” or the “\n \n Company\n \n ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today that it has filed a preliminary short form prospectus (the “\n \n Preliminary Prospectus\n \n ”) with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with an offering (the “\n \n Offering\n \n ”) of common shares of the Company (“\n \n Common Shares\n \n ”) and/or pre-funded common share purchase warrants of the Company (“\n \n Pre-Funded Warrants\n \n ” and, together with the Common Shares, the “\n \n Securities\n \n ”) in lieu of Common Shares.\n \n\n The Offering is expected to be completed on a commercially reasonable efforts agency basis pursuant to an agency agreement to be entered into between the Company and Bloom Burton Securities Inc. (“\n \n Bloom Burton\n \n ” or the “\n \n Agent\n \n ”). The number of Securities to be distributed, the size of the Offering and the price of each Common Share and Pre-Funded Warrant will be determined by negotiation between the Company and Bloom Burton in the context of the market with final terms to be determined at the time of pricing.\n \n\n The Company intends to use the net proceeds from the Offering to obtain US FDA 510(k) clearance of the next generation Novasight Hybrid system, as well as complete a limited market release and initiate a broader commercial launch in the United States. The Company also intends to use the net proceeds for working capital and other general corporate purposes.\n \n\n The Offering is expected to close on or about December 12, 2025 (the “\n \n Closing Date\n \n ”) or such later date as may be agreed upon by the Company and Bloom Burton. The Of...